NO311896B1 - Fremgangsmate for aktivering av et normalt transkripsjonelt ikke uttrykt gen i genomet til en eukaryotisk cellelinje, fremgangsmate for modifisering av ekspresjonskarakteristikken, genom fra en eukaryotisk cellelinje, en ikke differensierende eukaryot cel - Google Patents
Fremgangsmate for aktivering av et normalt transkripsjonelt ikke uttrykt gen i genomet til en eukaryotisk cellelinje, fremgangsmate for modifisering av ekspresjonskarakteristikken, genom fra en eukaryotisk cellelinje, en ikke differensierende eukaryot cel Download PDFInfo
- Publication number
- NO311896B1 NO311896B1 NO19922436A NO922436A NO311896B1 NO 311896 B1 NO311896 B1 NO 311896B1 NO 19922436 A NO19922436 A NO 19922436A NO 922436 A NO922436 A NO 922436A NO 311896 B1 NO311896 B1 NO 311896B1
- Authority
- NO
- Norway
- Prior art keywords
- gene
- dna
- cell line
- genome
- segment
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 436
- 230000014509 gene expression Effects 0.000 title claims description 113
- 238000000034 method Methods 0.000 title claims description 83
- 210000003527 eukaryotic cell Anatomy 0.000 title claims description 17
- 230000003213 activating effect Effects 0.000 title claims description 11
- 108020004414 DNA Proteins 0.000 claims description 283
- 210000004027 cell Anatomy 0.000 claims description 231
- 230000001105 regulatory effect Effects 0.000 claims description 118
- 230000006801 homologous recombination Effects 0.000 claims description 73
- 238000002744 homologous recombination Methods 0.000 claims description 73
- 239000003550 marker Substances 0.000 claims description 73
- 230000008685 targeting Effects 0.000 claims description 71
- 238000010276 construction Methods 0.000 claims description 39
- 238000003780 insertion Methods 0.000 claims description 21
- 230000037431 insertion Effects 0.000 claims description 21
- 238000011144 upstream manufacturing Methods 0.000 claims description 21
- 230000003321 amplification Effects 0.000 claims description 16
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 16
- 229930193140 Neomycin Natural products 0.000 claims description 6
- 229960004927 neomycin Drugs 0.000 claims description 6
- 230000004936 stimulating effect Effects 0.000 claims description 6
- 241000700584 Simplexvirus Species 0.000 claims description 4
- 108020004440 Thymidine kinase Proteins 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 108700026220 vif Genes Proteins 0.000 claims description 2
- 108091092724 Noncoding DNA Proteins 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 description 42
- 239000013612 plasmid Substances 0.000 description 39
- 238000013518 transcription Methods 0.000 description 33
- 230000035897 transcription Effects 0.000 description 33
- 239000000047 product Substances 0.000 description 32
- 239000002299 complementary DNA Substances 0.000 description 30
- 229920002477 rna polymer Polymers 0.000 description 30
- 238000003752 polymerase chain reaction Methods 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 21
- 108020004999 messenger RNA Proteins 0.000 description 18
- 238000001890 transfection Methods 0.000 description 18
- 239000013598 vector Substances 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 16
- 241000700159 Rattus Species 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- 244000005700 microbiome Species 0.000 description 12
- 230000001817 pituitary effect Effects 0.000 description 11
- 108091026890 Coding region Proteins 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 230000010354 integration Effects 0.000 description 9
- 239000000499 gel Substances 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 7
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 239000003623 enhancer Substances 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000006798 recombination Effects 0.000 description 7
- 238000005215 recombination Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 6
- 241001045988 Neogene Species 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 101150091879 neo gene Proteins 0.000 description 6
- 210000004940 nucleus Anatomy 0.000 description 6
- 239000013615 primer Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000007999 Nuclear Proteins Human genes 0.000 description 5
- 108010089610 Nuclear Proteins Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000010353 genetic engineering Methods 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 101000868151 Rattus norvegicus Somatotropin Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 3
- 102000055025 Adenosine deaminases Human genes 0.000 description 3
- 108010017826 DNA Polymerase I Proteins 0.000 description 3
- 102000004594 DNA Polymerase I Human genes 0.000 description 3
- 230000004543 DNA replication Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010051696 Growth Hormone Proteins 0.000 description 3
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 3
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 102100038803 Somatotropin Human genes 0.000 description 3
- 108010022394 Threonine synthase Proteins 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 108010068678 beta Subunit Thyrotropin Proteins 0.000 description 3
- 101150055766 cat gene Proteins 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 102000004419 dihydrofolate reductase Human genes 0.000 description 3
- 229960002963 ganciclovir Drugs 0.000 description 3
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 3
- 102000034356 gene-regulatory proteins Human genes 0.000 description 3
- 108091006104 gene-regulatory proteins Proteins 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000000122 growth hormone Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101710082464 Cis-aconitate decarboxylase Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 101710147299 DNA fragmentation factor subunit beta Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 108010025815 Kanamycin Kinase Proteins 0.000 description 2
- 108010047956 Nucleosomes Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- 101710145525 Probable cinnamyl alcohol dehydrogenase Proteins 0.000 description 2
- 239000013616 RNA primer Substances 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 101100421709 Schistosoma mansoni SM21.7 gene Proteins 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000001623 nucleosome Anatomy 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000001915 proofreading effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000003584 silencer Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- 102100024436 Caldesmon Human genes 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000016559 DNA Primase Human genes 0.000 description 1
- 108010092681 DNA Primase Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 102100033417 Glucocorticoid receptor Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- -1 MDR Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101000708422 Podarcis siculus Tissue- and phase-specific nuclear protein Proteins 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 102100024819 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 102000006646 aminoglycoside phosphotransferase Human genes 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000008316 intracellular mechanism Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 108091008569 nuclear steroid hormone receptors Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 102000004217 thyroid hormone receptors Human genes 0.000 description 1
- 108090000721 thyroid hormone receptors Proteins 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45478389A | 1989-12-22 | 1989-12-22 | |
PCT/US1990/007642 WO1991009955A1 (en) | 1989-12-22 | 1990-12-21 | Endogenous gene expression modification with regulatory element |
Publications (3)
Publication Number | Publication Date |
---|---|
NO922436L NO922436L (no) | 1992-06-19 |
NO922436D0 NO922436D0 (no) | 1992-06-19 |
NO311896B1 true NO311896B1 (no) | 2002-02-11 |
Family
ID=23806064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19922436A NO311896B1 (no) | 1989-12-22 | 1992-06-19 | Fremgangsmate for aktivering av et normalt transkripsjonelt ikke uttrykt gen i genomet til en eukaryotisk cellelinje, fremgangsmate for modifisering av ekspresjonskarakteristikken, genom fra en eukaryotisk cellelinje, en ikke differensierende eukaryot cel |
Country Status (26)
Country | Link |
---|---|
EP (5) | EP1484412A3 (ru) |
JP (3) | JP3501286B2 (ru) |
KR (1) | KR0176693B1 (ru) |
AR (1) | AR245776A1 (ru) |
AT (2) | ATE156189T1 (ru) |
AU (1) | AU645294B2 (ru) |
BG (1) | BG60624B1 (ru) |
BR (1) | BR9007937A (ru) |
CA (1) | CA2071989C (ru) |
DE (3) | DE69031172T2 (ru) |
DK (2) | DK0505500T3 (ru) |
ES (2) | ES2104690T3 (ru) |
FI (1) | FI107391B (ru) |
GR (1) | GR3025057T3 (ru) |
HK (2) | HK1000547A1 (ru) |
HU (1) | HU217212B (ru) |
IL (4) | IL116046A (ru) |
LT (1) | LT3998B (ru) |
LV (1) | LV10655B (ru) |
NO (1) | NO311896B1 (ru) |
OA (1) | OA09594A (ru) |
RO (1) | RO109864B1 (ru) |
RU (1) | RU2128227C1 (ru) |
UA (1) | UA42675C2 (ru) |
WO (1) | WO1991009955A1 (ru) |
ZA (1) | ZA9010392B (ru) |
Families Citing this family (157)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6048729A (en) * | 1987-05-01 | 2000-04-11 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
DK0747485T3 (da) * | 1989-11-06 | 1999-08-16 | Cell Genesys Inc | Fremstilling af proteiner ved anvendelse af homolog rekombination |
US5643753A (en) | 1990-04-18 | 1997-07-01 | Connaught Laboratories Limited | Use of autologous promoters to express gene products in bordetella |
GB9008746D0 (en) * | 1990-04-18 | 1990-06-13 | Connaught Lab | The use of autologous promoters to express gene products in bordetella |
CA2102628A1 (en) * | 1991-05-06 | 1992-11-07 | Stephen Sherwin | Gene manipulation and expression using genomic elements |
US5968502A (en) * | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US6054288A (en) * | 1991-11-05 | 2000-04-25 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
US6270989B1 (en) | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
US6692737B1 (en) | 1991-11-05 | 2004-02-17 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
US6063630A (en) | 1991-11-05 | 2000-05-16 | Transkaryotic Therapies, Inc. | Targeted introduction of DNA into primary or secondary cells and their use for gene therapy |
PT101031B (pt) | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | Processo para o fornecimento de proteinas por terapia genetica |
US5641670A (en) * | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
WO1993023553A1 (en) * | 1992-05-19 | 1993-11-25 | Exemplar Corporation | Production of transgenics by joining regulatory and coding regions in vivo |
AU4401993A (en) * | 1992-06-04 | 1993-12-30 | Exemplar Corporation | Insertion of heterologous dna outside of known chromosomal genes |
US6670178B1 (en) | 1992-07-10 | 2003-12-30 | Transkaryotic Therapies, Inc. | In Vivo production and delivery of insulinotropin for gene therapy |
US6531124B1 (en) | 1992-07-10 | 2003-03-11 | Transkaryotic Therapies, Inc. | In vivo production and delivery of insulinotropin for gene therapy |
TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
DK153992D0 (da) * | 1992-12-22 | 1992-12-22 | Novo Nordisk As | Metode |
US5733753A (en) * | 1992-12-22 | 1998-03-31 | Novo Nordisk A/S | Amplification of genomic DNA by site specific integration of a selectable marker construct |
GB2299336A (en) * | 1993-12-23 | 1996-10-02 | Merck & Co Inc | Homologous recombination antibody expression sysstem for murine cells |
AU738395B2 (en) * | 1994-05-13 | 2001-09-20 | Transkaryotic Therapies, Inc. | DNA construct for effecting homologous recombination and uses thereof |
US6350730B1 (en) | 1994-08-17 | 2002-02-26 | The Rockefeller University | OB polypeptides and modified forms as modulators of body weight |
US6001968A (en) * | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
US6048837A (en) * | 1994-08-17 | 2000-04-11 | The Rockefeller University | OB polypeptides as modulators of body weight |
US6471956B1 (en) | 1994-08-17 | 2002-10-29 | The Rockefeller University | Ob polypeptides, modified forms and compositions thereto |
US6124439A (en) * | 1994-08-17 | 2000-09-26 | The Rockefeller University | OB polypeptide antibodies and method of making |
US6124448A (en) * | 1994-08-17 | 2000-09-26 | The Rockfeller University | Nucleic acid primers and probes for the mammalian OB gene |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US6645933B1 (en) | 1995-08-01 | 2003-11-11 | Helsinki University Licensing Ltd. Oy | Receptor ligand VEGF-C |
US6130071A (en) * | 1997-02-05 | 2000-10-10 | Helsinki University Licensing, Ltd. | Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof |
US6818220B1 (en) | 1994-11-14 | 2004-11-16 | Licentia Ltd. | Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof |
US6737513B1 (en) | 1996-06-07 | 2004-05-18 | Icos Corporation | Macrophage derived chemokine (MDC) and chemokine analogs and assay to identify modulators of MDC activity, and therapeutic uses for same |
US6498015B1 (en) | 1995-06-07 | 2002-12-24 | Icos Corporation | Methods of identifying agents that modulate the binding between MDC and an MDC receptor |
US7018627B1 (en) | 1995-06-07 | 2006-03-28 | Icos Corporation | Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof |
US6361946B1 (en) | 1997-02-05 | 2002-03-26 | Licentia Ltd | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
US7727761B2 (en) | 1995-08-01 | 2010-06-01 | Vegenics Limited | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
US7063958B1 (en) | 1996-01-16 | 2006-06-20 | The Rockefeller University | Nucleic acids db, the receptor for leptin |
US7084252B1 (en) | 1996-01-16 | 2006-08-01 | The Rockefeller University | DB, the receptor for leptin |
US7148004B1 (en) | 1997-01-16 | 2006-12-12 | The Rockefeller University | Oligonucleotides of the OB-R isoforms and methods of diagnosing body weight |
US7619079B2 (en) | 1996-02-14 | 2009-11-17 | The Rockefeller University | Db, the receptor for leptin, nucleic acids encoding the receptor, and uses thereof |
WO1998014592A2 (en) | 1996-10-01 | 1998-04-09 | Geron Corporation | Telomerase reverse transcriptase |
US5925544A (en) * | 1996-11-18 | 1999-07-20 | Novo Nordisk A/S | Method of homologous recombination followed by in vivo selection of DNA amplification |
US7125714B2 (en) | 1997-02-05 | 2006-10-24 | Licentia Ltd. | Progenitor cell materials and methods |
US5888809A (en) * | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
TR200000175T2 (tr) * | 1997-07-23 | 2001-01-22 | Roche Diagnostics Gmbh | Endogenik gen aktivasyonu ile eritropoietinin hazırlanması. |
KR100641969B1 (ko) | 1997-07-23 | 2006-11-06 | 로셰 디아그노스틱스 게엠베하 | 내인성 유전자 활성화에 의한 에리트로포이에틴의제조방법 |
US6548296B1 (en) | 1997-07-23 | 2003-04-15 | Roche Diagnostics Gmbh | Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof |
US6897066B1 (en) | 1997-09-26 | 2005-05-24 | Athersys, Inc. | Compositions and methods for non-targeted activation of endogenous genes |
US5932465A (en) * | 1997-10-16 | 1999-08-03 | Icos Corporation | Phosphodiesterase 8A |
AU757930B2 (en) * | 1997-12-01 | 2003-03-13 | Roche Diagnostics Gmbh | Optimization of cells for endogenous gene activation |
CA2321224A1 (en) | 1998-02-23 | 1999-08-26 | Icos Corporation | Phosphodiesterase 10 |
US6479256B1 (en) | 1998-03-04 | 2002-11-12 | Icos Corporation | Lectomedin materials and methods |
US6200951B1 (en) | 1998-03-12 | 2001-03-13 | Icos Corporation | Chitinase chitin-binding fragments |
US6541623B1 (en) | 1998-04-03 | 2003-04-01 | Hyseq, Inc. | Interleukin—1 receptor antagonist and uses thereof |
US6337072B1 (en) | 1998-04-03 | 2002-01-08 | Hyseq, Inc. | Interleukin-1 receptor antagonist and recombinant production thereof |
US6294655B1 (en) | 1998-04-03 | 2001-09-25 | Hyseq, Inc. | Anti-interleukin-1 receptor antagonist antibodies and uses thereof |
US6426191B1 (en) | 1998-04-03 | 2002-07-30 | Hyseq, Inc. | Assays involving an IL-1 receptor antagonist |
US6071691A (en) * | 1998-04-27 | 2000-06-06 | Oregon Health Science University | Materials and methods for modulating differentiation |
US6492138B1 (en) | 1998-05-21 | 2002-12-10 | Amgen Canada Inc. | Polynucleotides encoding a novel SHC-binding protein |
EP1080210A2 (en) * | 1998-05-27 | 2001-03-07 | Novo Nordisk Biotech, Inc. | Methods for producing a polypeptide by modifying the copy number of a gene |
US6387645B1 (en) | 1998-07-16 | 2002-05-14 | Hyseq, Inc. | Methods and materials relating to novel CD39-like polypeptides |
JP2002520040A (ja) | 1998-07-16 | 2002-07-09 | ハイセック,インコーポレーテッド | 新規cd39様ポリペプチドに関する方法および材料 |
US6476211B1 (en) | 1998-07-16 | 2002-11-05 | Hyseq, Inc. | Methods and materials relating to CD39-like polypeptides |
US6447771B1 (en) | 1999-03-19 | 2002-09-10 | Hyseq, Inc. | Methods and materials relating to novel CD39-like polypeptides |
US6773911B1 (en) | 1998-11-23 | 2004-08-10 | Amgen Canada Inc. | Apoptosis-inducing factor |
DE19857609A1 (de) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
WO2000038536A2 (en) | 1998-12-23 | 2000-07-06 | Mount Sinai School Of Medicine Of New York University | Inhibitors of the bitter taste response |
US6350447B1 (en) | 1999-01-29 | 2002-02-26 | Hyseq, Inc. | Methods and compositions relating to CD39-like polypeptides and nucleic acids |
US6783959B1 (en) | 1999-01-29 | 2004-08-31 | Nuvelo, Inc. | Methods and compositions relating to CD39-like polypeptides and nucleic acids |
US6899875B1 (en) | 1999-01-29 | 2005-05-31 | Nuvelo, Inc. | Methods and compositions relating to CD39-like polypeptides and nucleic acids |
US6780977B1 (en) | 1999-01-29 | 2004-08-24 | Nuvelo, Inc. | Methods and compositions relating to CD39-like polypeptides and nucleic acids |
IL144960A0 (en) * | 1999-02-19 | 2002-06-30 | Athersys Inc | Compositions and methods for non-targeted activation of endogenous genes |
US6335013B1 (en) | 1999-03-19 | 2002-01-01 | Hyseq, Inc. | Methods and materials relating to CD39-like polypeptides |
WO2000058479A1 (en) | 1999-03-26 | 2000-10-05 | Amgen Inc. | Beta secretase genes and polypeptides |
CN1370238A (zh) | 1999-06-16 | 2002-09-18 | 艾科斯有限公司 | 人聚(adp-核酸)聚合酶2的物质和方法 |
US6632665B1 (en) | 1999-08-09 | 2003-10-14 | Wake Forest University | Human gene encoding 3′-5′ exonuclease |
US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
US7408047B1 (en) | 1999-09-07 | 2008-08-05 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
US6900043B1 (en) | 1999-09-21 | 2005-05-31 | Amgen Inc. | Phosphatases which activate map kinase pathways |
US6344549B1 (en) | 1999-10-14 | 2002-02-05 | Icos Corporation | ATR-2 cell cycle checkpoint |
EP1222273A2 (en) | 1999-10-22 | 2002-07-17 | PHARMACIA & UPJOHN COMPANY | Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
US7314716B2 (en) | 1999-11-19 | 2008-01-01 | Mount Sinai School Of Medicine | Gustducin γ subunit materials and methods |
US6465620B1 (en) | 2000-01-21 | 2002-10-15 | Hyseq, Inc. | Methods and materials relating to novel von Willebrand/Thrombospondin-like polypeptides and polynucleotides |
US6586390B1 (en) | 2000-01-21 | 2003-07-01 | Hyseq, Inc. | Methods and materials relating to novel prothrombinase-like polypeptides and polynucleotides |
US6635742B1 (en) | 2000-01-25 | 2003-10-21 | Nuvelo, Inc. | Antibodies specific for semaphorin-like polypeptides |
TW201006846A (en) | 2000-03-07 | 2010-02-16 | Senomyx Inc | T1R taste receptor and genes encidung same |
US7514239B2 (en) | 2000-03-28 | 2009-04-07 | Amgen Inc. | Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof |
WO2001090326A2 (en) | 2000-05-22 | 2001-11-29 | Pharmacia & Upjohn Company | Novel matrix metalloproteinases |
JP2004519205A (ja) | 2000-06-28 | 2004-07-02 | アムジェン インコーポレイテッド | 胸腺間質リンホポイエチンレセプター分子およびその使用 |
EP1307551A2 (en) | 2000-07-05 | 2003-05-07 | PHARMACIA & UPJOHN COMPANY | Human ion channels |
GB0018876D0 (en) * | 2000-08-01 | 2000-09-20 | Applied Research Systems | Method of producing polypeptides |
US6787684B2 (en) | 2000-10-16 | 2004-09-07 | E. & J. Gallo Winery | Lipoxygenase genes from Vitis vinifera |
DE60144439D1 (de) | 2000-12-20 | 2011-05-26 | Hoffmann La Roche | Konjugate von erythropoietin (epo) mit polyethylenglykol (peg) |
TW201022287A (en) | 2001-01-03 | 2010-06-16 | Senomyx Inc | T1R taste receptors and genes encoding same |
US7883856B2 (en) | 2001-04-05 | 2011-02-08 | Senomyx Inc. | Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators |
US7803982B2 (en) | 2001-04-20 | 2010-09-28 | The Mount Sinai School Of Medicine Of New York University | T1R3 transgenic animals, cells and related methods |
DK1407787T3 (da) | 2001-06-20 | 2009-06-02 | Dainippon Sumitomo Pharma Co | Fremgangsmåde til fremme af nukleinsyreoverförsel |
EP2003451B1 (en) | 2001-06-26 | 2012-05-30 | Senomyx, Inc. | T1r1-t1r3 hetero-oligomeric umami taste receptors and cell lines that express said receptors and use thereof for identification of umami taste compounds |
CN1610830A (zh) | 2001-07-10 | 2005-04-27 | 塞诺米克斯公司 | 特异性t2r味觉受体在鉴定阻断苦味觉的化合物中的应用 |
US7662924B2 (en) | 2002-02-22 | 2010-02-16 | The Board Of Trustees Of The University Of Illinois | Beta chain-associated regulator of apoptosis |
US7205398B2 (en) | 2002-05-24 | 2007-04-17 | Schering-Plough Animal Health Corporation | Eta-1 gene and methods for use |
US7459435B2 (en) | 2002-08-29 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
MXPA05003869A (es) | 2002-10-08 | 2005-06-22 | Ares Trading Sa | El uso de citocina capaz de enlazarse a la proteina de union a interleucina-18, y de inhibir la actividad de una segunda citocina. |
US7459436B2 (en) | 2002-11-22 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
CA2802143C (en) | 2003-01-14 | 2018-06-19 | Dana-Farber Cancer Institute | Sparc encoding polynucleotide as a cancer therapy sensitizer |
AU2004256023B2 (en) | 2003-06-27 | 2008-03-13 | Monell Chemical Senses Center | Taste receptors of the T1R family from domestic cat |
CA2900181C (en) | 2003-08-06 | 2019-01-29 | Catherine Tachdjian | Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof |
MXPA06003234A (es) | 2003-09-29 | 2006-06-08 | Warren Pharmaceuticals Inc | Citosinas protectoras de los tejidos para el tratamiento y prevencion de la sepsis y la formacion de adhesiones. |
US20080318319A1 (en) * | 2003-12-19 | 2008-12-25 | Yoshiko Minakuchi | Novel Method of Nucleic Acid Transfer |
EP1753864A2 (en) | 2004-04-14 | 2007-02-21 | Monell Chemical Senses Center | Taste receptors of the t1r family from domestic dog |
ES2530694T3 (es) | 2004-04-23 | 2015-03-04 | Zoetis P & U Llc | Factor de permisividad celular para virus, y usos del mismo |
IL161673A0 (en) | 2004-04-29 | 2004-09-27 | Applied Research Systems | Compositions and methods for therapy of chemotherapy-induced neuropathy |
US7893034B2 (en) | 2004-09-02 | 2011-02-22 | Yale University | Regulation of oncogenes by microRNAs |
WO2006066064A2 (en) | 2004-12-13 | 2006-06-22 | Monell Chemical Senses Center | A voltage-gated, ph-sensitive anion channel and its novel splice variant involved in taste sensation |
EP3072522B1 (en) | 2005-01-06 | 2019-04-24 | Novo Nordisk A/S | Anti-kir combination treatments and methods |
US7531523B2 (en) | 2005-02-17 | 2009-05-12 | Vertex Pharmaceuticals Incorporated | Sodium channel protein type III alpha-subunit splice variant |
SI2567976T1 (sl) | 2005-03-23 | 2017-11-30 | Genmab A/S | Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma |
WO2007002528A1 (en) | 2005-06-23 | 2007-01-04 | Yale University | Anti-aging micrornas |
CA2612613A1 (en) | 2005-09-14 | 2007-03-22 | Mara Rossi | Method for the determination of poloxamers |
US7972813B2 (en) | 2005-09-30 | 2011-07-05 | Vertex Pharmaceuticals Incorporated | Tetrodotoxin-resistant sodium channel alpha subunit |
JP5342878B2 (ja) | 2005-10-20 | 2013-11-13 | セノミクス・インコーポレーテッド | キメラヒト甘味‐旨味および旨味‐甘味味覚受容体 |
CA2630782C (en) | 2005-12-08 | 2015-02-03 | Amgen Inc. | Improved host cells and culture methods |
DE102006004008A1 (de) | 2006-01-27 | 2007-08-02 | Hannelore Prof. Dr. Dr. Ehrenreich | Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose |
US8148536B2 (en) | 2006-04-21 | 2012-04-03 | Senomyx, Inc. | Comestible compositions comprising high potency savory flavorants, and processes for producing them |
JP5277243B2 (ja) | 2007-05-11 | 2013-08-28 | トーマス・ジェファーソン・ユニバーシティ | 神経変性疾患および障害を治療および阻止する方法 |
KR101563753B1 (ko) | 2007-05-11 | 2015-10-27 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 피부 궤양의 치료 방법 |
CL2008002053A1 (es) | 2007-07-17 | 2009-05-22 | Hoffmann La Roche | Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion. |
AR067536A1 (es) | 2007-07-17 | 2009-10-14 | Hoffmann La Roche | Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea |
WO2009010107A1 (en) | 2007-07-19 | 2009-01-22 | Hannelore Ehrenreich | Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis |
DK2191271T3 (en) | 2007-07-27 | 2016-04-11 | Univ Gent | PERMISSIVE CELLS AND APPLICATIONS THEREOF |
CA2696995C (en) | 2007-08-21 | 2017-11-21 | Senomyx, Inc. | Identification of human t2r receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof |
GB0803076D0 (en) | 2008-02-20 | 2008-03-26 | Univ Ghent | Mucosal Membrane Receptor and uses thereof |
JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
MX341149B (es) | 2008-10-10 | 2016-08-09 | Amgen Inc | Mutantes fgf21 y uso de los mismos. |
UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
CA2760674A1 (en) | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
PE20120358A1 (es) | 2009-05-05 | 2012-04-26 | Amgen Inc | Mutantes fgf21 y usos de los mismos |
US20120264688A1 (en) | 2009-09-23 | 2012-10-18 | Walter Hinderer | Process for the purification of recombinant human erythropoietin (epo), epo thus purified and pharmaceutical compositions comprising same |
EP2325194A1 (en) | 2009-11-24 | 2011-05-25 | Glycotope GmbH | Process for the purification of glycoproteins |
UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
EP2528933A1 (en) | 2010-01-28 | 2012-12-05 | Glycotope GmbH | Process for the purification of glycoproteins |
MX2012011986A (es) | 2010-04-15 | 2013-03-05 | Amgen Inc | RECEPTOR FGF HUMANO Y PROTEINAS ENLAZADAS A ß-KLOTHO. |
LT2580243T (lt) | 2010-06-09 | 2020-01-27 | Genmab A/S | Antikūnai prieš žmogaus cd38 |
CA2802782C (en) | 2010-06-15 | 2018-03-13 | Genmab A/S | Human antibody drug conjugates against tissue factor |
JP5735650B2 (ja) | 2010-09-14 | 2015-06-17 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Peg化エリスロポエチンを精製するための方法 |
US8759313B2 (en) | 2011-08-03 | 2014-06-24 | The Charlotte-Mecklenburg Hospital Authority | Treatment of fibrosis using microRNA 19b |
WO2013003697A1 (en) | 2011-06-30 | 2013-01-03 | Trustees Of Boston University | Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1) |
WO2013009971A1 (en) | 2011-07-12 | 2013-01-17 | E. I. Du Pont De Nemours And Company | Detection and screening method and materials useful in performance thereof |
IN2014MN00974A (ru) | 2011-12-16 | 2015-04-24 | Targetgene Biotechnologies Ltd | |
JP2016527911A (ja) | 2013-08-20 | 2016-09-15 | レック・ファーマシューティカルズ・ディー・ディーLek Pharmaceuticals D.D. | ポリペプチドのα−アミド化および/またはC末端アミノ酸開裂を制御するための細胞培養用培地およびプロセス |
EP3194581A4 (en) | 2014-09-15 | 2018-04-25 | Children's Medical Center Corporation | Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation |
CA3027143A1 (en) | 2016-07-15 | 2018-01-18 | F. Hoffmann-La Roche Ag | Method for purifying pegylated erythropoietin |
ES2905105T3 (es) | 2017-12-29 | 2022-04-07 | Hoffmann La Roche | Procedimiento para proporcionar una composición de proteína PEGilada |
CN111727063A (zh) | 2017-12-29 | 2020-09-29 | 豪夫迈·罗氏有限公司 | 用于提供聚乙二醇化蛋白质组合物的方法 |
JP7137625B2 (ja) | 2017-12-29 | 2022-09-14 | エフ.ホフマン-ラ ロシュ アーゲー | Peg化タンパク質組成物を提供するための方法 |
WO2022159414A1 (en) | 2021-01-22 | 2022-07-28 | University Of Rochester | Erythropoietin for gastroinfestinal dysfunction |
WO2024091824A1 (en) | 2022-10-26 | 2024-05-02 | Ada Forsyth Institute, Inc. | Differentiation and reprogramming of chondrocyte |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0225887B1 (en) * | 1985-04-08 | 1994-06-08 | Amgen Inc. | A method and a hybrid promoter for controlling exogenous gene transcription |
EP0273085A1 (en) * | 1986-12-29 | 1988-07-06 | IntraCel Corporation | A method for internalizing nucleic acids into eukaryotic cells |
ZA88319B (en) * | 1987-02-06 | 1988-08-12 | Lubrizol Enterprises, Inc. | Ocs enhancer |
GB8807683D0 (en) * | 1988-03-31 | 1988-05-05 | Ici Plc | Regulation of gene expression |
FR2646438B1 (fr) * | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
WO1991005052A1 (en) * | 1989-09-28 | 1991-04-18 | Leningradsky Gosudarstvenny Universitet | Method for obtaining a polypeptide with human-interleukin-2 activity, secreted by yeast cells, saccharomyces cerevisiae |
DK0747485T3 (da) * | 1989-11-06 | 1999-08-16 | Cell Genesys Inc | Fremstilling af proteiner ved anvendelse af homolog rekombination |
PT101031B (pt) | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | Processo para o fornecimento de proteinas por terapia genetica |
-
1990
- 1990-12-21 DE DE69031172T patent/DE69031172T2/de not_active Expired - Fee Related
- 1990-12-21 EP EP04075825A patent/EP1484412A3/en not_active Withdrawn
- 1990-12-21 EP EP91903051A patent/EP0505500B1/en not_active Revoked
- 1990-12-21 EP EP96203412A patent/EP0779362B2/en not_active Expired - Lifetime
- 1990-12-21 DE DE69034135T patent/DE69034135T3/de not_active Expired - Lifetime
- 1990-12-21 WO PCT/US1990/007642 patent/WO1991009955A1/en not_active Application Discontinuation
- 1990-12-21 CA CA002071989A patent/CA2071989C/en not_active Expired - Lifetime
- 1990-12-21 KR KR1019920701467A patent/KR0176693B1/ko not_active IP Right Cessation
- 1990-12-21 AU AU71836/91A patent/AU645294B2/en not_active Expired
- 1990-12-21 AT AT91903051T patent/ATE156189T1/de not_active IP Right Cessation
- 1990-12-21 AT AT96203412T patent/ATE264916T1/de not_active IP Right Cessation
- 1990-12-21 JP JP50331291A patent/JP3501286B2/ja not_active Expired - Lifetime
- 1990-12-21 HU HU9202068A patent/HU217212B/hu unknown
- 1990-12-21 DK DK91903051.0T patent/DK0505500T3/da active
- 1990-12-21 ES ES91903051T patent/ES2104690T3/es not_active Expired - Lifetime
- 1990-12-21 BR BR909007937A patent/BR9007937A/pt not_active Application Discontinuation
- 1990-12-21 DE DE0779362T patent/DE779362T1/de active Pending
- 1990-12-21 RU SU5052496A patent/RU2128227C1/ru active
- 1990-12-21 RO RO92-0843A patent/RO109864B1/ro unknown
- 1990-12-21 ES ES96203412T patent/ES2151463T5/es not_active Expired - Lifetime
- 1990-12-21 UA UA93004446A patent/UA42675C2/ru unknown
- 1990-12-21 DK DK96203412.0T patent/DK0779362T4/da active
- 1990-12-21 EP EP03102675A patent/EP1375666A3/en not_active Withdrawn
- 1990-12-21 EP EP04075824A patent/EP1482053A3/en not_active Withdrawn
- 1990-12-23 IL IL116046A patent/IL116046A/en not_active IP Right Cessation
- 1990-12-23 IL IL96765A patent/IL96765A0/xx not_active IP Right Cessation
- 1990-12-24 AR AR90318726A patent/AR245776A1/es active
- 1990-12-27 ZA ZA9010392A patent/ZA9010392B/xx unknown
-
1992
- 1992-06-18 FI FI922863A patent/FI107391B/fi active
- 1992-06-19 NO NO19922436A patent/NO311896B1/no not_active IP Right Cessation
- 1992-06-19 OA OA60234A patent/OA09594A/en unknown
- 1992-06-22 BG BG96515A patent/BG60624B1/bg unknown
-
1993
- 1993-01-13 LV LVP-93-27A patent/LV10655B/en unknown
- 1993-12-15 LT LTIP1595A patent/LT3998B/lt not_active IP Right Cessation
-
1995
- 1995-11-17 IL IL11604695A patent/IL116046A0/xx active IP Right Grant
-
1997
- 1997-10-15 GR GR970402703T patent/GR3025057T3/el unknown
- 1997-11-01 HK HK97102072A patent/HK1000547A1/xx not_active IP Right Cessation
- 1997-12-02 HK HK97102307A patent/HK1000786A1/xx not_active IP Right Cessation
-
2003
- 2003-06-06 JP JP2003162768A patent/JP3740134B2/ja not_active Expired - Lifetime
- 2003-11-05 JP JP2003375791A patent/JP2004089200A/ja active Pending
-
2004
- 2004-09-23 IL IL16425204A patent/IL164252A0/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO311896B1 (no) | Fremgangsmate for aktivering av et normalt transkripsjonelt ikke uttrykt gen i genomet til en eukaryotisk cellelinje, fremgangsmate for modifisering av ekspresjonskarakteristikken, genom fra en eukaryotisk cellelinje, en ikke differensierende eukaryot cel | |
US5272071A (en) | Method for the modification of the expression characteristics of an endogenous gene of a given cell line | |
US5591601A (en) | DNA polymerase gene expression system utilizing an RNA polymerase co-delivered with the gene expression vector system | |
JP2023018093A (ja) | 標的核酸の改変のための改善された方法 | |
JPH0678784A (ja) | 遺伝子生産物の製造方法 | |
EP1613758B1 (en) | Delivery of nucleic acids into eukaryotic genomes using in vitro assembled mu transposition complexes | |
Class et al. | Patent application title: TEVI CHIMERIC ENDONUCLEASE AND THEIR PREFERENTIAL CLEAVAGE SITES Inventors: George Silva (Le Plessis-Trevise, FR) Marine Beurdeley (Paris, FR) | |
WO2024076688A2 (en) | Synthetic genomic safe harbors and methods thereof | |
KR20240029020A (ko) | Dna 변형을 위한 crispr-트랜스포손 시스템 | |
CN104774860A (zh) | 适于转化细胞的构建体、系统及其应用 | |
US20070031920A1 (en) | High expression locus vector based on ferritin heavy chain gene locus | |
Bennett et al. | Replication of a linear mini-chromosome with terminal inverted repeats from the Kluyveromyces lactis linear DNA plasmid k2 in the cytoplasm of Saccharomyces cerevisiae | |
Wang et al. | REPRINT WITH PERMISSION ONLY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CREP | Change of representative |
Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS |
|
CREP | Change of representative |
Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO, NO |
|
MK1K | Patent expired |